RxDoctor Payments Data

Melissa Callihan, APRN

Family · Ironton, OHNPI 1093272437

Payments from drug & device makers

$1,598in general payments, 2019–2025

Across 88 payments — averaging $18.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$766
  • AbbVie$373
  • Lilly USA, LLC$259
  • Amgen$59
  • Pfizer$38
  • Novo Nordisk$30
  • plus $72 from 4 others

What the payments were for

  • Food & beverage$1,597100%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,598 in reported general payments places this provider in the 75th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$551
Medicare patients
25
Services billed
62

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide33$55,130
TrulicityDulaglutide23$47,528
JardianceEmpagliflozin26$37,969
MounjaroTirzepatide15$26,296
FarxigaDapagliflozin Propanediol16$24,048
EliquisApixaban11$17,414
Repatha SyringeEvolocumab27$13,530
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$2,406
Venlafaxine Hcl ErVenlafaxine Hcl17$1,740
Albuterol Sulfate HfaAlbuterol Sulfate19$933
Levothyroxine Sodium44$892
Rosuvastatin Calcium58$770
Omeprazole55$598
Gabapentin50$469
Buspirone Hcl24$392

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$259$73,82438 claims
Novo NordiskOzempic$30$55,13033 claims
Boehringer IngelheimJardiance$28$37,96926 claims
AstraZenecaFarxiga$766$24,04816 claims
PfizerEliquis$38$17,41411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 6,812 family providers in Ohio.

Other family in Ironton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →